An open‐label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function

Publisher： John Wiley & Sons Inc

E-ISSN： 2160-7648|4|4|256-261

ISSN： 2160-763X

Source： Clinical Pharmacology In Drug Development, Vol.4, Iss.4, 2015-07, pp. : 256-261

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics and Safety of Ebastine in Patients with Impaired Hepatic Function Compared with Healthy Volunteers: A Phase I Open-Label Study

By Lasseter K.C.  

Clinical Pharmacokinetics, Vol. 43, Iss. 2, 2004-01 ,pp. : 121-129

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Gepirone in Subjects with Normal Renal Function and in Patients with Chronic Renal Dysfunction

By Dogterom P.  

Clinical Drug Investigation, Vol. 22, Iss. 8, 2002-08 ,pp. : 513-522

Adis International

Access to resources Recommend Favorite

Effects of Rifampicin (Rifampin) on the Pharmacokinetics and Safety of Ambrisentan in Healthy Subjects: A Single-Sequence, Open-Label Study

By Harrison Brooke  

Clinical Drug Investigation, Vol. 30, Iss. 12, 2010-12 ,pp. : 875-885

Adis International

Access to resources Recommend Favorite

Pharmacokinetics, Safety and Tolerance of Voriconazole in Renally Impaired Subjects: Two Prospective, Multicentre, Open-Label, Parallel-Group Volunteer Studies

By Abel Samantha  

Clinical Drug Investigation, Vol. 28, Iss. 7, 2008-01 ,pp. : 409-420

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Orally Administered Single- and Multiple-Dose Olopatadine in Healthy Chinese Subjects: An Open-Label Study

By Chu Nan-Nan   Chen Wei-Li   Xu Hong-Rong   Li Xue-Ning  

Clinical Drug Investigation, Vol. 29, Iss. 7, 2009-06 ,pp. : 451-457

Adis International

Access to resources Recommend Favorite